Investing.com - UroGen Pharma reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
UroGen Pharma announced earnings per share of $-1.13 on revenue of $16.01M. Analysts polled by Investing.com EPS of $-1.16 on revenue of $20.15M.
UroGen Pharma 's are down 24% and is trading at $9.50 , still down 43.37% from its 52 week high of $19.37 set on Friday, November 12, 2021.
UroGen Pharma shares lost 13.40% to trade at $9.50 in pre-market trade the report.
UroGen Pharma follows other major Healthcare sector earnings this month
UroGen Pharma's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar